Related Experiment Video
Updated: Oct 2, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Prenatal levo-alpha-acetylmethadol (LAAM) and/or naloxone: effects on brain chemistry and postweaning behavior
Female rats were treated daily with water or 0.2 mg LAAM/kg (PO) beginning 3 weeks before mating and continuing until parturition, after which addicted neonates were allowed to withdraw spontaneously. Beginning on the 14th day of gestation half of the animals in each group were injected (SC) 4 and 2 hours earlier with naloxone (Nx, 1 or 5 mg/kg) and the others with saline. Treatment with LAAM retarded maternal weight gain prior to mating but not during gestation. Evidence of dependence in the LAAM treated dams was manifest as a transient but robust weight loss following each dose of Nx. Offspring exposed to LAAM whose mothers were injected with Nx demonstrated significant perinatal mortality but survivors showed no evidence of growth retardation or biochemical and behavioral dysfunction. Pups exposed only to LAAM and withdrawn after birth showed some evidence of congenital effects. These include (1) lower 21 day postnatal body weights, (2) lower 1 and 3 day postnatal brain weights, (3) lower 19 day fetal brain protein concentrations, (4) lower 1 day postnatal brain DNA, RNA and protein content, and (5) lower levels of unconditioned exploratory activity at 1 1/2 and 10 months of age. The effects on growth and brain weight and biochemical parameters were transient, since control values were attained by 21 or 45 days of age. The absence of these effects in subjects exposed to both LAAM and Nx is interpreted as a screening effect of in utero withdrawal, with only the most resistant subjects surviving to be tested, the result of less severe spontaneous withdrawal because of displacement of cumulated LAAM metabolites by Nx or habituation to postnatal withdrawal stress by precipitated in utero withdrawal.
Female rats were treated daily with water or 0.2 mg LAAM/kg (PO) beginning 3 weeks before mating and continuing until parturition, after which addicted neonates were allowed to withdraw spontaneously. Beginning on the 14th day of gestation half of the animals in each group were injected (SC) 4 and 2 hours earlier with naloxone (Nx, 1 or 5 mg/kg) and the others with saline. Treatment with LAAM retarded maternal weight gain prior to mating but not during gestation. Evidence of dependence in the LAAM treated dams was manifest as a transient but robust weight loss following each dose of Nx. Offspring exposed to LAAM whose mothers were injected with Nx demonstrated significant perinatal mortality but survivors showed no evidence of growth retardation or biochemical and behavioral dysfunction. Pups exposed only to LAAM and withdrawn after birth showed some evidence of congenital effects. These include (1) lower 21 day postnatal body weights, (2) lower 1 and 3 day postnatal brain weights, (3) lower 19 day fetal brain protein concentrations, (4) lower 1 day postnatal brain DNA, RNA and protein content, and (5) lower levels of unconditioned exploratory activity at 1 1/2 and 10 months of age. The effects on growth and brain weight and biochemical parameters were transient, since control values were attained by 21 or 45 days of age. The absence of these effects in subjects exposed to both LAAM and Nx is interpreted as a screening effect of in utero withdrawal, with only the most resistant subjects surviving to be tested, the result of less severe spontaneous withdrawal because of displacement of cumulated LAAM metabolites by Nx or habituation to postnatal withdrawal stress by precipitated in utero withdrawal.
More Related Videos
15:27Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development
Published on: July 13, 2014
05:13Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
Related Concept Videos
Drugs Affecting Neurotransmitter Synthesis
Drug Abuse and Addiction: Pharmacological Phenomena